Immunotherapy combo shows promise for tough pituitary tumors

NCT ID NCT04042753

Completed Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tested two immunotherapy drugs, nivolumab and ipilimumab, in 10 patients with aggressive pituitary tumors that worsened after surgery and radiation. The goal was to see if the combination could shrink tumors or slow their growth. Researchers also monitored side effects closely.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nivolumab and ipilimumab (immunotherapy drugs)
What this could lead to: If it works, this could offer a new treatment option for people with aggressive pituitary tumors that have not responded to standard therapies.
What could go wrong: This is a very small early-phase trial with only 10 participants, so results may not apply to everyone. Immunotherapy can cause serious side effects like inflammation of organs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGGRESSIVE PITUITARY TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypophysitis pituitary adenocarcinoma pituitary cancer pituitary gland disorder Pituitary Neoplasms pituitary tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PITUITARY PITUITARY CANCER PITUITARY CARCINOMA PITUITARY TUMOR

Contacts and locations

Locations

Cedars-Sinai Medical Center

Los Angeles, California, 90048, United States
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Bergen (Limited Protocol Activities)

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center (All Protocol Activities)

New York, New York, 10021, United States
Memorial Sloan Kettering Cancer Center @ Commack (Limited Protocol Activities)

Commack, New York, 11725, United States
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau (Limited Protocol Activities)

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Westchester (Limited Protocol Activities)

Harrison, New York, 10604, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.